178 related articles for article (PubMed ID: 15094443)
1. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging.
Gopinath G; Ahmed A; Buscombe JR; Dickson JC; Caplin ME; Hilson AJ
Nucl Med Commun; 2004 Mar; 25(3):253-7. PubMed ID: 15094443
[TBL] [Abstract][Full Text] [Related]
2. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
3. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
Wong KK; Cahill JM; Frey KA; Avram AM
Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
[TBL] [Abstract][Full Text] [Related]
4. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
5. Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹In-Pentetreotide Quantitative SPECT/CT.
Rowe SP; Vicente E; Anizan N; Wang H; Leal JP; Lodge MA; Frey EC; Wahl RL
J Nucl Med; 2015 Jul; 56(7):985-8. PubMed ID: 25977467
[TBL] [Abstract][Full Text] [Related]
6. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
7. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms.
Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789
[TBL] [Abstract][Full Text] [Related]
8. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
9. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours.
Hillel PG; van Beek EJ; Taylor C; Lorenz E; Bax ND; Prakash V; Tindale WB
Clin Radiol; 2006 Jul; 61(7):579-87. PubMed ID: 16784943
[TBL] [Abstract][Full Text] [Related]
10. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
11. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384
[TBL] [Abstract][Full Text] [Related]
12. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
14. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
[TBL] [Abstract][Full Text] [Related]
15. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study.
Quigley AM; Buscombe JR; Shah T; Gnanasegaran G; Roberts D; Caplin ME; Hilson AJ
Neuroendocrinology; 2005; 82(3-4):215-20. PubMed ID: 16601361
[TBL] [Abstract][Full Text] [Related]
16. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
18. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
19. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
[TBL] [Abstract][Full Text] [Related]
20. Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids.
Schillaci O; Scopinaro F; Danieli R; Angeletti S; Tavolaro R; Annibale B; Cannas P; Marignani M; Colella AC; Delle Fave G
Anticancer Res; 1997; 17(3B):1753-6. PubMed ID: 9179229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
